Faculty

 
Director
Ash Tewari, MBBS, MCh

System Chair, Milton & Carroll Petrie Department of Urology

Director of Robotic Prostatectomy, Precision UrologyTM & Men’s Health, Mount Sinai Health System

Director, Prostate Cancer Program, The Barbara and Maurice A. Deane Prostate Health and Research Center, Mount Sinai Health System

Professor of Urology, Department of Urology at the Icahn School of Medicine at Mount Sinai

 

Ashutosh (Ash) K. Tewari, MD, is a world-renowned urologist and prostate cancer specialist. He serves as Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, where he also directs the Department of Urology and leads a multidisciplinary team dedicated to advancing prostate cancer treatment, research, and education. In addition, he is Director of the Center of Excellence for Prostate Cancer at the Mount Sinai Tisch Cancer Center.

Dr. Tewari has performed more than 5,000 robotic radical prostatectomy procedures. His laboratory focuses on identifying the genomic drivers of prostate cancer and translating genomic discoveries into practical clinical applications, particularly through advanced imaging techniques.

In 2012, he received the American Urological Association’s Gold Cystoscope Award, an honor given annually to a urologist who has made significant contributions to the field within 10 years of completing residency. He also holds numerous leadership roles both in the United States and internationally.

Dr. Tewari earned his undergraduate and medical degrees from GSVM Medical College in Kanpur, India, where he received 17 gold medals for outstanding academic performance. He completed his first urology residency at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lucknow, India.

He then pursued fellowships in urologic oncology at the University of California, San Francisco and the University of Florida in Gainesville. In 2004, he completed a second urology residency at Henry Ford Hospital in Detroit, Michigan. During his time there, he was part of the team that performed the first robotic radical prostatectomy in the United States.

Dr. Tewari’s research addresses prostate cancer from multiple angles. His outcomes research group studies the epidemiological impact of the disease. He also investigates novel imaging approaches to identify prostate cancer biomarkers and continues his work on uncovering the genomic causes of the disease.

He has authored more than 250 peer-reviewed articles, book chapters, and textbooks focused on prostate cancer and robotic surgery. His work includes publications in leading journals such as Nature, Cell, and PNAS. Most recently, he edited Prostate Cancer: A Comprehensive Perspective (Elsevier, 2013).

 

Research Interest: Prostate Cancer

Expertise: Prostate Cancer, Kidney Cancer, Laparoscopic Techniques, Robotic Surgery, Cystoscopy, Prostatectomy, Prostate Biopsy

 
FACULTY SESSIONS
 
  • Friday, February 19th 1:40–2:50 pm

    Prostate Session II – Retzius Sparing

    Moderator

    Avoiding the Retzius structures involved in continence and potency preservation and passing through the pouch of Douglas can be oncologically safe and can result in high early continence and potency rates.

  • Saturday, February 20th 8:10–10:20 am

    Prostate Session III – Single Port

    Moderator

    Surgical treatment for prostate cancer is transforming. The novel da Vinci Surgical System for single port system is safe and feasible. The approach presents satisfactory outcomes for: operative time, hospital stay, pain requirements, catheterisation time, and complications. Patients have reported favourable ratings for scar cosmesis as compared to conventional laparoscopic or open approaches after kidney surgery.